Outcome of MMMTs is determined primarily by depth of invasion and stage. As with endometrial carcinomas, the prognosis is influenced by the grade and type of the adenocarcinoma, being poorest with serous differentiation. MMMTs are highly malignant; a stage I<unk>  has an expected five-year survival rate of 50%, while the overall five-year survival rate is less than 20%. Staging of Uterine MMMTs is as follows: *Stage I. Carcinoma is confined to the corpus uteri itself. *Stage II. Carcinoma involves the corpus and the cervix. *Stage III. Carcinoma extends outside the uterus but not outside the lesser pelvis. *Stage IV. Carcinoma extends outside the true pelvis or involves the mucosa of the bladder or the rectum. A Cochrane review indicates women with high stage uterine carcinosarcoma (stage 3 or 4) who were treated with combination chemotherapy including Ifosfamide, were at lower risk of disease progression and death than those women treated with Ifosfamide alone. However, more women experienced side effects with combination therapy than with ifosamide alone. Radiotherapy to the abdomen was not associated with improved survival.
Mixed Müllerian tumor
Leydig cell tumour
Theca lutein cyst
Epididymal cyst
Gonadoblastoma
Ovarian germ cell tumors
Corpus luteum cyst
Endolymphatic sac tumor